AZD1656

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AzetidinesPyrazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Design and Development of the Glucokinase Activator AZD1656
 
Is this relevant?
2018
2018
Synthesis of AZD1656
 
Is this relevant?
2014
2014
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a…
AIMS To study the effect of exogenous i.m. glucagon on recovery from controlled insulin-induced hypoglycaemia in patients with… (More)
Is this relevant?
Review
2014
Review
2014
Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.
Glucose-phosphorylating enzyme, glucokinase (GK) plays a major role in glucose homeostasis primarily through its regulatory… (More)
Is this relevant?
2013
2013
Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin.
AIM To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin (HbA1c) as an add-on to metformin in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.
AIM To assess the glucose-lowering effects of monotherapy with the glucokinase activator AZD1656 in Japanese patients with type 2… (More)
Is this relevant?
2012
2012
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
OBJECTIVES AZD1656 is a novel glucokinase activator with a postulated dual mechanism of action by activating glucokinase in both… (More)
Is this relevant?
2012
2012
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
CONTEXT Glucokinase is expressed in the hypothalamus, but effects of glucokinase activators (GKAs) on counterregulatory responses… (More)
Is this relevant?
2012
2012
Property based optimisation of glucokinase activators – discovery of the phase IIb clinical candidate AZD1656
Oral Glucose Tolerance Test Oral glucose tolerance tests were done on conscious Zucker obese fa/fa rats (age 12-13 weeks or older… (More)
Is this relevant?
2012
2012
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
AIMS To assess the safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator… (More)
Is this relevant?